Akers Biosciences Stock Forecast, Price & News

Akers Biosciences' stock was trading at $2.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKER stock has decreased by 19.0% and is now trading at $1.83.
View which stocks have been most impacted by COVID-19.

Wall Street analysts have given Akers Biosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akers Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Akers Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Akers Biosciences.

Akers Biosciences, Inc. (NASDAQ:AKER) issued its earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter. The medical instruments supplier earned $0.56 million during the quarter. Akers Biosciences had a negative return on equity of 87.42% and a negative net margin of 489.84%.
View Akers Biosciences' earnings history.

Akers Biosciences saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 536,600 shares, an increase of 12.2% from the September 30th total of 478,200 shares. Based on an average trading volume of 958,700 shares, the short-interest ratio is presently 0.6 days. Approximately 6.4% of the shares of the stock are sold short.
View Akers Biosciences' Short Interest.

Some companies that are related to Akers Biosciences include Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), ImmuCell (ICCC), ARCA biopharma (ABIO), Achieve Life Sciences (ACHV), StageZero Life Sciences (GNWSF), StageZero Life Sciences (GNWSD), BG Medicine (BGMD), Response Genetics (RGDXQ), Fuse Science (DROP) and FluoroPharma Medical (FPMI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu BioScience (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL).

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

Akers Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include We Are One Seven LLC (0.28%), Wedbush Securities Inc. (0.15%), Private Advisor Group LLC (0.14%) and First Allied Advisory Services Inc. (0.14%).
View institutional ownership trends for Akers Biosciences.

AKER stock was purchased by a variety of institutional investors in the last quarter, including We Are One Seven LLC, Wedbush Securities Inc., Private Advisor Group LLC, and First Allied Advisory Services Inc..
View insider buying and selling activity for Akers Biosciences.

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AKER stock can currently be purchased for approximately $1.83.

Akers Biosciences has a market capitalization of $16.21 million and generates $1.58 million in revenue each year. Akers Biosciences employs 12 workers across the globe.

The official website for Akers Biosciences is www.akersbio.com.

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected]